The Food and Drug Administration yesterday released an updated enforcement policy related to face masks, barrier face coverings, face shields, surgical masks and respirators for the duration of the COVID-19 public health emergency. The updates are intended to expand these products’ availability to the general public and health care personnel. The revised guidance adds barrier face coverings to its current face mask policy, allowing for the distribution and use of face masks and barrier face coverings for medical purpose even though those products may not be in compliance with certain regulatory requirements — so long as the use of those products does not create an undue risk. In an additional effort to bolster supply, the FDA states that it generally does not intend to object to the distribution of stockpiled, non-NIOSH-approved respirators to be used as face masks for source control where such use does not create an undue risk. For examples of when undue risk is not created, please reference pages 8 and 9 of the enforcement policy. This policy will remain in effect until the end of the COVID-19 public health emergency. 

Related News Articles

Headline
The Agency for Healthcare Research and Quality seeks input through Nov. 12 on scientific evidence to inform a systematic review of telehealth use during…
Headline
The Centers for Disease Control and Prevention last week updated the list of underlying medical conditions that put adults of any age at higher risk for…
Chairperson's File
Working in health care delivery can be stressful and tiring under normal circumstances. And the COVID-19 pandemic has exerted incredible pressures on the…
Headline
The Department of Health and Human Services has renewed the COVID-19 public health emergency declaration for another 90 days effective Oct. 18. The extension…
Headline
The National Institutes of Health yesterday awarded a total of $78 million in funding to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2,…
Headline
Abbott Molecular Inc. yesterday issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and…